

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
Aeris Therapeutics, Inc.	04/12/2011
RECEIVING PARTY DATA	
Name:	Aeris Therapeutics, LLC
Street Address:	10K Gill Street
City:	Woburn
State/Country:	MASSACHUSETTS
Postal Code:	01801
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13493409
CORRESPONDENCE DATA	
Fax Number:	(617)832-1000
Phone:	617 832 1000
Email:	wherron@foleyhoag.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Foley Hoag LLP
Address Line 1:	155 Seaport Blvd
Address Line 2:	Patent Department
Address Line 4:	Boston, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	ATX-005.02
NAME OF SUBMITTER:	Wendy Herron
Total Attachments: 5 source=FHBOSTON-#4027271-v1-ATX-005_02_EXECUTED_ASSIGNMENT_AERIS_INC_TO_AERIS_LLC#page1.tif source=FHBOSTON-#4027271-v1-ATX-005_02_EXECUTED_ASSIGNMENT_AERIS_INC_TO_AERIS_LLC#page2.tif source=FHBOSTON-#4027271-v1-ATX-005_02_EXECUTED_ASSIGNMENT_AERIS_INC_TO_AERIS_LLC#page3.tif source=FHBOSTON-#4027271-v1-ATX-005_02_EXECUTED_ASSIGNMENT_AERIS_INC_TO_AERIS_LLC#page4.tif source=FHBOSTON-#4027271-v1-ATX-005_02_EXECUTED_ASSIGNMENT_AERIS_INC_TO_AERIS_LLC#page5.tif	

CH \$40.00 13493409

ASSIGNMENT

WHEREAS, Aeris Therapeutics, Inc., whose address is 10K Gill Street, Woburn, MA 01801, ("*Assignor*") is the owner of the entire right, title and interest in and to the patent applications listed in the attached Exhibit A ("*Patent Applications*") and to the inventions therein described ("*Inventions*"); and

WHEREAS, Aeris Therapeutics, LLC, whose address is 10K Gill Street, Woburn, MA 01801, ("*Assignee*"), is desirous of acquiring the entire right, title and interest in and to the Patent Applications and the Inventions; and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor, intending to be legally bound, does hereby assign and transfer to the Assignee, the entire right, title and interest, in the Patent Applications and Inventions, including any and all continuations, divisionals, continuations-in-part and any other applications claiming priority to the patent applications listed in Exhibit A and all rights to claim priority based thereon, all rights to file foreign applications on the Inventions, and all letters patents and reissues thereof, issuing for the Inventions in the United States of America and in any and all foreign countries, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; together with all income, royalties, damages or payments due or payable, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Applications and Inventions, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives (the "*Assignment*").

It is agreed that the Assignor shall be legally bound, upon reasonable request of the Assignee, or its successors, assigns or legal representatives, to supply information and evidence of which the undersigned has knowledge or possession, relating to the making and practice of the Patent Applications and Inventions, to testify in any legal proceeding relating thereto, to execute all instruments proper to prosecute the Patent Applications or

patent the Inventions in the United States of America and foreign countries in the name of the Assignee, and to execute all instruments proper to carry out the intent of this instrument.

IN WITNESS WHEREOF, intending to be legally bound hereby, the parties have duly executed this Assignment.

Aeris Therapeutics, Inc.

Dated: 12 April 2011

By: [Signature]
Name: DAVID DOWE
Title: CEO

This 12 day of April, 2011, before me personally came the before-mentioned known as the individual who executed the foregoing Assignment, who acknowledged to me that he executed the same of his own free will for the purposes and consideration therein expressed, and in the capacity therein set forth.

Witness my hand and Notarial seal the day and year immediately above-written.

[Signature]
Notary Public




Exhibit A

Docket No.	Title	Jurisdiction	Application No.	Filing Date
ATX-003.01	Polymer Systems for Lung Volume Reduction Therapy	US	12/443021	26-Sep-07
ATX-003.25	Polymer Systems for Lung Volume Reduction Therapy	PCT	US07/079504	26-Sep-07
ATX-003.60	Polymer Systems for Lung Volume Reduction Therapy	US	60/847328	26-Sep-06
ATX-004.01	Polycation-Polyanion Complexes, Compositions and Methods of Use Thereof	US	11/590664	31-Oct-06
ATX-004.25	Polycation-Polyanion Complexes, Compositions and Methods of Use Thereof	PCT	US06/042338	31-Oct-06
ATX-004.60	Polycation Compositions and Therapeutic Uses Therefor	US	60/732987	2-Nov-05
ATX-005.01	Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers	US	12/117367	8-May-08
ATX-005.25	Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers	PCT	US08/062993	8-May-08
ATX-005.60	Lung Volume Reduction Therapy Using Crosslinked Aminated Polyvinyl Alcohol	US	60/917419	11-May-07
ATX-006.01	Pneumoreductive Therapy and Compositions Useful Therein	US	12/739791	27-Oct-08
ATX-006.25	Pneumoreductive Therapy and Compositions Useful Therein	PCT	US08/081321	27-Oct-08
ATX-006.60	Pneumoreductive Therapy and Compositions Useful Therein	US	60/982934	26-Oct-07
ATX-006.61	Pneumoreductive Therapy and Compositions Useful Therein	US	61/077209	1-Jul-08
ATX-007.01	Lung Volume Reduction Therapy Using Crosslinked Biopolymers	US	12/062189	3-Apr-08
ATX-007.25	Lung Volume Reduction Therapy Using Crosslinked Biopolymers	PCT	US08/059263	3-Apr-08

Docket No.	Title	Jurisdiction	Application No.	Filing Date
ATX-007.60	Lung Volume Reduction Therapy Using Crosslinked Mammalian Biopolymers	US	60/909806	3-Apr-07
ATX-011.01	Tissue Volume Reduction	US	09/379460	23-Aug-99
ATX-011.02	Tissue Volume Reduction	US	09/839253	20-Apr-01
ATX-011.03	Tissue Volume Reduction	US	10/069307	23-Aug-00
ATX-011.04	Tissue Volume Reduction	US	10/649232	26-Aug-03
ATX-011.05	Tissue Volume Reduction	US	11/009379	11-Dec-04
ATX-011.06	Tissue Volume Reduction	US	09/658338	8-Sep-00
ATX-011.25	Tissue Volume Reduction	PCT	US00/23134	23-Aug-00
ATX-012.01	Compositions and Methods for Reducing Lung Volume	US	10/464115	17-Jun-03
ATX-012.02	Compositions and Methods for Reducing Lung Volume	US	11/016548	17-Dec-04
ATX-012.25	Compositions and Methods for Reducing Lung Volume	PCT	US03/19339	17-Jun-03
ATX-012.28	Compositions and Methods for Reducing Lung Volume	PCT	US05/046016	19-Dec-05
ATX-012.60	Compositions and Methods for Reducing Lung Volume	US	60/389731	17-Jun-02
ATX-012.61	Compositions and Methods for Reducing Lung Volume	US	60/530832	17-Dec-03
ATX-013.01	Respiratory Assistance Apparatus and Method	US	11/824942	2-Jul-07
ATX-013.60	Respiratory Assistance Apparatus and Method	US	60/817987	30-Jun-06
ATX-013.61	Respiratory Assistance Apparatus and Method	US	60/818361	2-Jul-06
ATX-014.25	Formulations for Reducing Lung Volume	PCT	US06/013450	11-Apr-06
ATX-014.60	Formulations for Reducing Lung Volume	US	60/670396	11-Apr-05
ATX-015.60	Biodegradable Foams for Treating Emphysema	US	60/833860	26-Jul-06

Docket No.	Title	Jurisdiction	Application No.	Filing Date
ATX-016.01	Compositions and Methods for Treating Emphysema	US	10/386149	11-Mar-03
ATX-016.25	Compositions and Methods for Treating Emphysema	PCT	US03/07528	11-Mar-03
ATX-016.60	Compositions and Methods for Treating Emphysema	US	60/363118	11-Mar-02
ATX-017.60	Endobronchial Polymer-Based Treatment for Early-Stage Lung Cancer	US	61/146880	23-Jan-09
ATX-017.61	Endobronchial Polymer-Based Treatment for Cancer in the Lung	US	61/151623	11-Feb-09